This year, Market Scope has divided our “Year in Review” coverage across the January and February issues of the newsletter.
Area leads in eye care firms, technology, talent pool, and other lifestyle benefits.
Company expects 2016 revenues of $12.5 billion to $12.7 billion.
The first agreement cuts the wholesale list prices of branded prescription eye and skin products by 10 percent; the second reduces the price of more than 30 branded products to that of generics.
Pfizer CEO Ian Read said he is creating the infrastructure, even though the decision is two years away.
The 36,000-square-foot center features a fully equipped optometric training clinic and 12-station wet lab.
Overall, the IRS collected $1.4 billion in medical device taxes in 2013 and $1.9 billion in 2014.
Global revenues totaled $3.26 billion, an increase of 6 percent over 2014; cataract surgeries grew to nearly 24.4 million globally.
Several companies working on automated capsulotomy devices as alternative.
Japan continued to see a drop in interest for LASIK, though at a slower rate; other markets saw roughly flat demand or an upward tick.
Anti-VEGFs Lucentis and Eylea gained new indications; Ophthotech’s Fovista continued to create excitement; and Spark reported positive results.
Global revenues totaled nearly $1.8 billion for the year; Alcon saw robust demand for its market-leading Constellation.
FDA accepted Bausch + Lomb’s NDA for Vesneo in September 2015; Aerie allowed to alter the primary endpoint in Rhopressa’s second Phase III study.
Glaukos became first publicly traded MIGS company, while nearly 70,000 iStents were implanted in the US in 2015.
Introduction of OCT angiography provided visibility to additional structures in eye; Zeiss gained approval in this space with AngioPlex add-on for Cirrus 5000.
TearScience’s LipiFlow procedure showed impressive revenue gains; Ikervis was launched in Europe, while other drug candidates faced setbacks.
More than 75 firms manufacture ophthalmic diagnostic equipment; Carl Zeiss Meditec is the market leader in this segment with a 25 percent market share.
Revenues in the segment are estimated to total $2.8 billion in 2015.
The highly acclaimed ophthalmologist died Dec. 21, 2015, following a battle with glioblastoma.
Rhian Lewis was originally diagnosed with retinitis pigmentosa at age 5 and lost all of her vision six years before her implant procedure.
You are not currently logged in.
©2017 Market Scope
Lost your Password